You are here: Industry Insights > Ketamine

News List

Ketamine May Quickly Ease Tough-to-Treat Depression drugs
December 27, 2021
Ketamine, once most famous as a "club" drug, can rapidly improve hard-to-treat depression and curb suicidal thoughts, a new review confirms.
iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products prnasia
November 25, 2021
iX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has...
Alcami to manufacture PharmaTher’s proprietary ketamine products CPhIonline
October 25, 2021
Three weeks after Alcami announced it was investing an additional $31 million to expand its sterile CDMO operation in Charleston, SC to increase its fill-finish and lyophilisation capacity...
Funding to support trial of ketamine in patients with bipolar depression europeanpharmaceuticalreview
June 22, 2021
The Canadian Government is funding studies to establish ketamine as a safe and effective treatment for patients with bipolar depression.
Neo Kuma sees early success on psychedelic healthcare investments firstwordpharma
June 04, 2021
NEO KUMA Ventures, the UK’s first investment fund dedicated solely to psychedelic healthcare, has today (3rd June) announced its investment in seven innovative healthcare companies.
Silo Pharma Enters Joint Venture with Zylo Therapeutics contractpharma
April 29, 2021
Silo Pharma Inc. a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has entered into a Joint Venture with Zylo Therapeutics.
Seelos Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine americanpharmaceuticalreview
December 30, 2019
Seelos Therapeutics announced the dosing of the first subjects in a Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) profile study, SLS-002-102.
Single Antidepressant Dose of Intravenous Ketamine Safe drugs
December 26, 2019
A single, low-dose ketamine infusion is relatively free of side effects for patients with treatment-resistant depression, according to research recently published in the Journal of Affective Disorders.
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA drugs
May 22, 2019
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA.
Health Highlights drugs
November 01, 2018
Ketamine Being Used as Unapproved Treatment for Depression

Previous page 1 2 Next page